We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Cellular Therapies for Immunosuppression

Nathalie Cools, Viggo F. I. Van Tendeloo and Zwi N. Berneman
*Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute,
 University of Antwerp
 Belgium*

1. Introduction

Almost all current therapeutic approaches to inhibit destructive immune responses in autoimmunity are based on antigen non-specific agents, such as cyclosporine A, which systemically suppress the function of virtually all immune effector cells. This indiscriminate immunosuppression, however, often causes serious and sometimes life-threatening side-effects. Indeed, long-term use of immunosuppressive drugs leads to nephrotoxicity and metabolic disorders, as well as manifestations of hyperimmunosuppression such as opportunistic infections and cancer. It is evident, that treatment would be greatly improved by targeting the fundamental cause of pathogenic immune responses in autoimmunity, i.e. loss of tolerance to self-antigens. For this, manipulation of the immune system in autoimmune diseases should ideally arise in specific tolerance for the self-antigens that stimulate chronic activation of the immune system resulting in long term remissions.

New – more antigen-specific and targeted - therapies are intensively being investigated for the treatment of human diseases (Sabatos-Peyton et al., 2010; Dazzi et al., 2007; Miller et al., 2007). In this context, a variety of cellular therapies have been designed to elicit or amplify immune responses. These cell-based activation immunotherapies have proven to be effective for cancer and infectious diseases. Although still in its infancy, the use of well specified and functionally characterized cellular products as treatment modality for autoimmune disorders and in transplantation tolerance is gaining interest. Indeed, experiences with hematopoietic stem cells and cell types with regulatory properties support the concept of resetting immune tolerance and have made cell-based therapies for autoimmune diseases a realistic alternative. At this point however, it is not yet clear which cell type among a broad arsenal of different tolerogenic entities is best with regard to safety, efficacy and related costs.

This review will explore the molecular and cellular mechanisms underlying T cell tolerance and will focus on emerging cell-based therapies pertaining to reduce, suppress or redirect existing immune responses to self-antigens in human diseases.

2. Control and regulation of immune responses

2.1 Tolerance induction

Immune tolerance is the process by which the body naturally does not launch an immune system attack against its own tissues. A variety of tolerance mechanisms have been

described to exist naturally and to be responsible for protection of the body's own tissue from immune injuries, while effectively fighting pathogens. Central tolerance to self-antigens results primarily from apoptotic deletion of autoreactive T cells during intrathymic T cell development (Burnet, 1959a; Burnet, 1959b). However, some limitations of this process have been observed resulting in escape of potentially autoreactive T cells (Steinman & Nussenzweig, 2002). Therefore additional mechanisms to induce tolerance occur in the periphery. These include (i) T cell anergy (i.e. the induction of functional hyporesponsiveness to antigens) (Schwartz, 2003), (ii) T cell deletion (i.e. the elimination of autoreactive T cells by apoptosis) (Kurts et al., 1998) and (iii) active suppression of the immune response by regulatory T cells (Cools et al., 2007a). Collectively these mechanisms are known as peripheral tolerance. Despite these mechanisms, some autoreactive T cells may escape and be present in the periphery. Their activation may lead to autoimmune disease. These diseases result in cell and tissue destruction by autoreactive T cells or autoantibodies and the accompanying inflammatory processes. Common autoimmune diseases include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes, multiple sclerosis (MS), Sjogren's syndrome, and inflammatory bowel disease (IBD).

2.2 T cell activation

The current paradigm is that the outcome of the immune response is determined by the relative balance between cells that are capable of causing tissue damage, such as T helper type 1 (Th1), type 2 (Th2) and type 17 (Th17) cells versus cells that are designed to suppress immune responses and limit damage, such as regulatory T cells (Treg). It is generally accepted that antigen-presenting cells (APC), particularly dendritic cells (DC), play a central role in the control and maintenance of this delicate balance depending on the level of inflammation in the microenvironment in which T cell activation takes place (Cools et al., 2007b).

(Auto)immune reactions are set in motion with the uptake, processing and presentation of self-antigens through APC. Nevertheless, it is commonly believed now that generation of T cell-mediated (auto)immunity requires a 3-signal T cell activation process (Curtsinger et al., 1999; Curtsinger et al., 2003) (Figure 1). The first signal is provided by the presentation of (self-)antigens by major histocompatibility complex (MHC) molecules on the APC to the T cell receptor (TCR) on the T cell. At this site, antigen recognition will take place which will create an immune synapse determining subsequent T cell fate. Next, interaction of costimulatory molecules on APC and T cells ensures appropriate activation of naïve T cells (Greenfield et al., 1998). For instance, the costimulatory factors CD80 and CD86 bind to CD28 on naïve T cells resulting in activation and proliferation of T cells. Absence of the second signal results in T cell anergy. Besides effector T cell activation, costimulation is also required for the activation and expansion of different regulatory T cell subsets (Salomon et al., 2000). Currently, it is generally accepted that (an) additional signal(s) (i.e. "signal 3"), such as CD40 ligation and/or the production of pro- or anti-inflammatory cytokines are involved in APC-driven polarization of naïve T cells into effector T cell populations. Indeed depending on the cytokines present upon T cell activation, naïve CD4⁺ T helper cells can acquire a variety of immune effector phenotypes (Strom & Koulmanda, 2009; Zhou et al., 2009). In brief, when CD4⁺ T cells are activated in the presence of interleukin (IL)-12, they become IFN- γ -producing Th1 cells; while CD4⁺ T cells that are activated in the presence of

IL-4 will differentiate into Th2 cells producing IL-4, IL-5 and IL-13. Expression of the transcription factor FOXP3 and subsequent generation of Treg is induced by transforming growth factor (TGF)- β , in the absence of additional pro-inflammatory cytokines. In contrast, expression of TGF- β in concert with IL-6 and IL-21 induces IL-17-producing T cells (Th17) (Bettelli et al., 2007; Weaver & Hatton, 2009; Jäger & Kuchroo, 2010).

Fig. 1. Molecular mechanisms of T cell activation. Currently, it is accepted that generation of T cell-mediated immunity requires at least 3 signals. In brief, antigen presentation (= "signal 1"), costimulation (= "signal 2"), and the production of immunoregulatory cytokines (= "signal 3") are required for the activation and expansion of different effector and regulatory T cell subsets

It might be evident that the immunological basis of the therapeutic effect of a variety of biological agents used for the induction of immunosuppression lies in the interaction with one, or more, of the above molecular signals. Therefore, immunosuppressants developed for their ability to alter T cell function can generally be divided into 3 categories: (i) TCR-directed agents, (ii) costimulatory antagonists, and (iii) antagonists of cytokines and cytokine receptors. First, Fc receptor (FcR)-non-binding CD3-specific antibodies carrying mutations of the IgG1 Fc chain with elimination of glycosylation sites, are minimally depleting and result in T cell apoptosis and anergy by altering the TCR-CD3 complex and/or induction of Treg. The early results from clinical trials using anti-CD3 antibodies, i.e. Otelixizumab (ChAgly CD3), Tepilizumab [hOKT3 γ 1(Ala-Ala)], and Visilizumab, in a variety of autoimmune disorders are encouraging (Keymeulen et al., 2005; Bisikirsha et al., 2005; Plevy et al., 2007). Second, agents that block T cell costimulation are currently being tested as maintenance drug in transplant patients. In this context, Abatacept (CTLA4-Ig) blocks the interaction between CD28 expressed on the surface of T cells and CD80/CD86 on

the surface of APC. Additionally, Alefacept interferes with the activation of T cells by preventing the interaction between CD2 on T cells and LFA-3 on APC (Vincenti & Luggen, 2007). Furthermore, cytokine- and/or cytokine receptor-directed therapies are also in development in order to promote immunosuppression. Indeed, TNF- α blockers have been extensively used and validated as an efficacious treatment for RA, Crohn's disease and psoriasis (Feldman et al., 1998; Victor et al., 2003). This approach clearly represents one of the greatest successes in biological response-modifying therapies. In addition, the therapeutic efficacy of an anti-IL-12/IL-23 (p40) monoclonal antibody (i.e. Ustekinumab) has been demonstrated in patients with active Crohn's disease (Mannon et al., 2004) and psoriasis (Krueger et al., 2007; Leonardi et al., 2008), but not in MS patients (Segal et al., 2008). For completeness, also biologicals that interfere with lymphocyte trafficking have been approved for the treatment of autoimmune disease. Thus far, the most successful drug in this class is Natalizumab, a monoclonal antibody to α 4-integrin (Yednock et al., 1992; Stüve et al., 2006) blocking the entry of leukocytes into the central nervous system. In addition, Fingolimod (FTY-720) holds promise as a new treatment for MS by promoting tissue retention (O'Connor et al., 2009). In fact, lymphocytes are trapped in the lymph nodes, which reduces peripheral lymphocyte counts and the recirculation of lymphocytes to the inflamed tissues (Mandala et al., 2002; Mehling et al., 2008).

Unlike conventional immunosuppressants for the treatment of patients with autoimmune diseases, biologicals only bind to immune cells or to products secreted by immune cells, thereby reducing or preventing toxicity to non-immune system tissues.

3. Cell therapy approaches aiming at minimizing T cell activation

At present, existing immunomodulatory drugs do not specifically target pathogenic autoreactive T lymphocytes. It is therefore evident, that the "holy grail" for the treatment of autoimmune disease is the development of treatment strategies in which only the pathogenic autoreactive T cells are safely inactivated in an antigen-specific manner, while leaving the remainder of the immune system undisturbed. Therefore, strong efforts are currently undertaken to circumvent various systemic side effects that may occur after overall modulation of protective immunity by harnessing peripheral regulatory mechanisms. Indeed, the anticipated induction of antigen-specific immunosuppression may operate via a number of cell-intrinsic (e.g. anergy) and/or cell-extrinsic (e.g. Treg) mechanisms. Potential candidate cell populations that bear immunomodulating and regulatory properties comprise stem cells of various origins, as well as immune cells such as Treg, DC, NKT and B cells.

3.1 Stem cells

3.1.1 Hematopoietic stem cells (HSC)

Hematopoietic stem cells (HSC) are cells capable of self-renewal and reconstitute all types of blood cells. For this, research on HSC is now providing new approaches to remove autoreactive immune cells and to subsequently generate a new, properly functioning immune system. Although the approach to use high dose myeloablative therapy combined with subsequent hematopoietic stem cell transplantation (HSCT) was first described more than 50 years ago for the treatment of malignant conditions, this principle was adopted in recent years for treatment of various autoimmune diseases. It is evident that complete

immunoablation is a drastic way to achieve maximal treatment efficiency in autoimmune diseases (Teng et al., 2005), with potentially lethal complications such as cardiotoxicity or overt opportunistic infections. For this, HSCT is only considered in patients suffering from severe and progressive autoimmune disease and refractory to conventional immunosuppressants. In contrast to complete ablation of autoreactive T cells, recent immune reconstituting data suggest that non-myeloablative or reduced intensity conditioning protocols could also allow the normal immune-regulatory mechanisms to recontrol the system (Muraro et al., 2005).

To obtain cells for autologous HSCT, stem cells are mobilized from the bone marrow to the peripheral blood, before patient conditioning, using various protocols [e.g. granulocyte colony-stimulating factor (G-CSF)]. Subsequently, the autologous HSC are collected through leukapheresis. After this, the patient is prepared for the transplant by potent immunosuppressive treatment, usually by chemotherapy and/or radiotherapy, in order to eliminate autoreactive T cells. Thereafter, peripheral blood cells or bone marrow cells enriched for HSC or previously purified CD34⁺ HSC are re-injected and newly developing B and T cells are introduced to self-antigens and controlled by the natural tolerance mechanisms. In most trials, the patient's own stem cells have been used (i.e. autologous HSCT), however small series and case reports of allogeneic HSCT have been reported (Oyama et al., 2001; Burt et al., 2004). Although the advantage of allogeneic HSCT is clear, namely introducing a "healthy" immune system, limited experience is available with regard to this approach for treatment of autoimmune disease. Indeed, the increased toxicity and potential risk of graft-versus-host disease (GVHD) is associated with significant morbidity and mortality of allogeneic HSCT (Griffith et al., 2006).

Several mechanisms may apply for correction of autoimmunity by HSCT. As mentioned above, potent immunosuppressive treatment attributes to the elimination of autoreactive T and B cells. However, incomplete immunoablation may account for the suboptimal responses and high risk rates of early relapse seen in some clinical trials of autologous HSCT. Although HSCT targets a wide array of immune effector cells non-specifically, it has become evident that the therapeutic efficacy of HSCT cannot merely be the consequence of the profound immunosuppression. In contrast, resetting of the abnormal immune regulation underlying the autoimmune conditions most likely attributes to the success of this therapeutic approach. This was well illustrated by Traynor and colleagues who found that following HSCT the deregulated T cell receptor repertoires were restored to those of healthy individuals (Traynor et al., 2000). From this, it can be postulated that re-establishing tolerance in T cells contributes to the beneficial effect of HSCT and thereby decreases the likelihood of disease re-occurrence. Besides the risk associated with allogeneic HSCT, this approach is associated with durable and complete remission in a small number of patients. It is postulated that elimination of autoreactive host lymphocytes by allogeneic donor T cells contributes to this beneficial effect, known as graft-versus-autoimmunity (GVA) effect. However, as stated above, this benefit comes with the associated risk of GVHD. Furthermore tolerance to self-antigens, after allogeneic HSCT, may also be achieved by mixed hematopoietic chimerism, i.e. a state in which HSC of the recipient and donor co-exist and thus also multi-lineage hematopoietic populations. When both donor and host cells contribute to hematopoiesis, the new T cell repertoire in the recipient thymus is rendered tolerant to antigens expressed by hematopoietic cells of both origins.

According to the EBMT/EULAR database (Daikeler et al., 2011), MS is the most frequent diagnosis for which HSCT is being used. Other indications are scleroderma, RA, juvenile idiopathic arthritis (JIA), SLE, Crohn's disease, ulcerative colitis, and vasculitis (Burt et al., 2003; Popat & Krance, 2004; Hough et al., 2005; Tyndall & Saccardi, 2005). Today, HSCT can induce long-term remission lasting for more than six years without any treatment and with a significant decrease in the risks of HSCT, in particular for patients with severe autoimmune disease refractory to conventional treatment. Nonetheless, the major limitation of HSCT in autoimmune patients remains that a considerable amount of treatment-related complications have been reported (e.g. infections, graft failure and malignant relapses), which accounted for the majority of the transplant-related mortality. Currently, several phase III clinical trials are ongoing to evaluate the prospects of autologous HSCT as a cellular treatment strategy for severe autoimmune disease.

3.1.2 Mesenchymal stromal cells (MSC)

Recently another cell, the mesenchymal stromal cell (MSC), has generated great interest for its ability to induce immunosuppression. In pioneering studies, Friedenstein et al. reported more than 30 years ago fibroblast-like cells that could be isolated from bone marrow via their inherent adherence to plastic in culture (Friedenstein et al., 1974). MSC are now known as cells of stromal origin that have the ability of self-renewal and multipotency, which allows their differentiation into various tissues of mesodermal origin (osteocytes, chondrocytes and adipocytes) and other embryonic lineages, and may be isolated from bone marrow, skeletal muscle, adipose tissue, synovial membranes and other connective tissues, and blood. Although still subject of debate, MSC are defined by using a combination of phenotypic markers and functional properties. A generally accepted phenotypic profile of human MSC includes the expression of CD73, CD105 and CD90 as well as the absence of expression of hematopoietic (CD45) and vascular (CD31) markers (Pittenger et al., 1999; Dominici et al., 2006).

MSC are relatively non-immunogenic, i.e. they do not normally express MHC or costimulatory molecules such as CD80 and CD86. Moreover, MSC exert a profound immunosuppressive and anti-inflammatory effect *in vitro* and *in vivo*, which has made these cells of particular interest for therapeutic application (Marigo & Dazzi, 2011). The mechanisms underlying the immunosuppressive effect of MSC remain to be clarified. However, it has been demonstrated that preliminary "licensing" of MSC by inflammatory environmental conditions, such as IFN- γ , is needed to acquire their immunosuppressive properties (Jones et al., 2007). In turn, MSC skew the inflammatory environment into an anti-inflammatory environment both directly, through mechanisms mediated by soluble factors [TGF- β (Di Nicola et al., 2002), indoleamine 2,3-dioxygenase (IDO) (Meisel et al., 2004), hepatocyte growth factor (HGF) (Di Nicola et al., 2002), nitric oxide (Sato et al., 2007), IL-10 (Batten et al., 2006) and prostaglandin E2 (Aggarwal & Pittenger, 2005)] and cell contact [e.g. via the inhibitory molecule programmed death 1 (PD-1) (Augello et al., 2005)], and indirectly via the recruitment of other regulatory networks that involve APC (Beyth et al., 2005) and Treg (Prevosto et al., 2007). Although MSC-induced unresponsiveness lacks any selectivity, its effect is directed mainly at the level of T cell proliferation, as evidenced by cell cycle arrest of MSC-induced anergic T cells. Additionally, recent studies suggest that MSC may induce a cytokine profile shift in the Th1/Th2 balance towards the anti-inflammatory Th2 phenotype (Haniffa et al., 2007; Zhou et al., 2008). Indeed, MSC have been

shown to decrease the production of IFN- γ , IL-2 and TNF- α , whilst they increase IL-4 secretion (Aggarwal & Pittenger, 2005). Furthermore, MSC suppress the cytolytic effects of cytotoxic T cells (Rasmusson et al., 2003). However, the effects of MSC on immune responses are not confined to T cells. Indeed, it has been demonstrated that MSC are also capable of inhibiting proliferation of IL-2- and IL-15-stimulated natural killer (NK) cells (Sotiropoulou et al., 2006; Spaggiari et al., 2006), as well as alter the function of B cells and APC. Indeed, MSC affect terminal differentiation of B cells demonstrated by an altered release of humoral factors. Moreover, they increase B cell viability, while inhibiting B cell proliferation through cell cycle arrest of B lymphocytes in the G0/G1 phase (Tabera et al., 2008; Asari et al., 2009). In addition, MSC-derived prostaglandin E2 was shown to act on macrophages by stimulating the production of IL-10 (Németh et al., 2009) and on monocytes by blocking their differentiation towards DC as well as on dendritic cell maturation and function, as demonstrated by a decreased cell-surface expression of MHC class II and costimulatory molecules, and a decreased production of IL-12 and TNF- α (Spaggiari et al., 2009; Jiang et al., 2005; Nauta et al., 2006). Finally, MSC have been reported to promote both *in vitro* and *in vivo*, the formation of potent CD4⁺CD25⁺ as well as CD8⁺ Treg (Prevosto et al., 2007; Maccario et al., 2005), although the precise mode of action is still subject of active research.

Although better understanding of the underlying mechanisms is still required, accumulating evidence with regard to their immunomodulatory properties suggests that MSC have great potential to suppress immune responses in various clinical settings. While MSC represent only a rare fraction in bone marrow and other tissues (i.e. 0.001-0.01% of the total nucleated cells), they can be expanded *ex vivo*, under clinical-grade conditions, to significant numbers from a small bone marrow aspirate in 8 to 10 weeks (DiGirolamo et al., 1999; Sekiya et al., 2002). Treatment of several auto-immune diseases, such as type 1 diabetes, RA, MS (Zappia et al., 2005), and GVHD (Le Blanc et al., 2004; Le Blanc et al., 2008; Lazarus et al., 2005) was performed with administration of MSC derived from allogeneic donors. Several phase I and II clinical trials have been conducted, and encouraging results have been generated from these studies. For example, it has recently been demonstrated that MSC may promote reconstitution of the bone marrow stroma after chemotherapy and enhance HSC engraftment. Indeed, sustained hematopoietic engraftment in pediatric patients was shown after co-transplantation of donor MSC with allogeneic HSC (Ball et al., 2007). In addition, MSC infusion has resulted in striking improvement of therapy-resistant, acute GVHD, as demonstrated by a complete response of 30 out of 55 patients in a multi-center phase II clinical trial (LeBlanc et al., 2008). Although clinical results obtained so far confirm feasibility and safety of the *in vivo* application of MSC without major adverse events, another report has shown an increased risk of relapse in leukemia patients who were co-transplanted with MSC in order to prevent acute GVHD after allogeneic HSCT (Ning et al., 2008), as compared with patients receiving standard HSCT.

3.2 Dendritic cells

A major therapeutic goal in autoimmune diseases is to provide inhibitory mechanisms with the capacity to suppress inappropriate immune activation in an antigen-specific manner with minimal risk and damage to the host. In this perspective, we discuss the role of dendritic cells (DC) and regulatory T cells (Treg) in the design of new cell-based and antigen-specific therapeutic strategies to suppress autoreactive immune responses.

DC are a highly specialized population of white blood cells that are capable of orchestrating the adaptive immune responses (Cools et al., 2007b). In their immature state, DC reside in the peripheral tissues (skin, airways and intestine) where they function as the “sentinels” of the immune system, i.e. they patrol the body to capture antigens, including self-antigens, invading pathogens and certain malignant cells. In the classical view, antigen-loaded DC migrate to the secondary lymphoid organs and the internalized antigen is processed and presented to T cells in a MHC-dependent manner (Trombetta et al., 2005). Depending on the context in which the antigen was captured, DC induce tolerance or immunity. Indeed, in a steady-state condition DC remain immature, expressing only small amounts of MHC and costimulatory molecules, and are believed to induce T cell anergy or regulatory T cells (Lutz & Schuler, 2002). Upon encounter of so-called danger signals, DC undergo a complex maturation process from antigen-capturing cells into antigen-presenting cells, essential for triggering T cell proliferation and differentiation into helper and effector T cells with unique functions and cytokine profiles.

DC are heterogeneous and can be divided into two major subsets: plasmacytoid DC and conventional or myeloid DC, which show several distinct phenotypic and biological features (O’Doherty et al., 1994). Plasmacytoid DC (pDC) originate from a lymphoid progenitor cell in lymphoid organs and are characterized by the production of high amounts of type I interferon in response to viral stimuli (Cella et al., 1999). For this, pDC are believed to be primarily involved in innate immunity (Swiecki & Colonna, 2010; Reizis et al., 2011). On the other hand, a myeloid progenitor cell differentiates towards different DC populations in the bone marrow (Liu, 2001). Subsequently, DC subsets circulate throughout the body: Langerhans cells migrate towards the skin epidermis and interstitial DC migrate towards the skin dermis and various other tissues (airways, liver and intestine). Circulating or migrating DC are found in the blood and in the afferent lymphatics, respectively. In human blood, differences in DC subsets can be identified based on a different expression of Toll-like Receptors (TLR) (Kadowaki et al., 2001), cytokine receptors and cytokines (Kohrgruber et al., 1999), as well as a difference in migratory potential (Penna et al., 2001), indicating a different function in induction and regulation of the immune response by various subtypes [for review on DC subsets see (Ju et al., 2010)].

DC appear to be essential for both central tolerance in the thymus and peripheral tolerance (Liu et al., 2007). Indeed, mature thymic DC present self-antigens to developing T and B cells and subsequently delete lymphocytes with autoreactivity above a certain threshold (Steinman et al., 2003). In addition, DC induce peripheral tolerance through induction of T cell anergy and T cell deletion and through activation of Treg. Antigen presentation in the absence of costimulation can lead to impaired clonal expansion and T cell anergy (Schwartz, 2003). Furthermore, there is increasing evidence that under steady-state conditions antigen presentation by immature DC leads to T cell deletion and peripheral tolerance. In this context, a discrete subset of human DC expressing indoleamine 2,3-dioxygenase (IDO) have been identified (Munn et al., 2002; Mellor & Munn, 2004). IDO is a catabolic enzyme responsible for the degradation of tryptophan, an amino acid essential for T cell proliferation. Additionally, signalling through CD95 (Fas ligation) by DC may be involved in tolerance induction (Süss & Shortman, 1996). Finally, it has also been documented that DC are able to prime Treg in order to maintain tolerance to self-antigens, foreign peptides and allo-antigens (Banerjee et al., 2006; Fehérvári & Sakaguchi, 2004; Kretschmer et al., 2005).

While the pivotal role of DC in immunity is clearly established and results of early studies using DC-based therapeutic vaccines in cancer patients (Van Tendeloo et al., 2011) and HIV-infected individuals (Connolly et al., 2008) are encouraging, the fact that DC are also involved in tolerance induction has provided the prospect for the use of DC to suppress noxious immune responses in allergy, autoimmunity and transplantation (Hilkens et al., 2010). Dendritic cell-based immunotherapeutic strategies for autoimmune and allergic diseases can be developed either by targeting antigen to DC *in vivo* or by culturing the cells *in vitro*, pulsing with antigen and injecting them back into patients. On the one hand, antigens coupled to antibodies specific for DC markers, such as 33D1 or DEC-205, have already been used to deliver antigens to DC *in vivo*, resulting in antigen-specific tolerance which in contrast could not be attained by injection of the same peptide in the Freund's adjuvant (Hawiger et al., 2001; Bonifaz et al., 2002). On the other hand, administration of immature DC has already been shown to induce antigen-specific T cell tolerance. Indeed, when iDC pulsed with influenza matrix protein (IMP) and keyhole limpet hemocyanin (KLH), a general stimulator of CD4⁺ T cells, were injected, a decline in influenza-specific CD8⁺ IFN- γ -secreting T cells was observed, while peptide-specific IL-10-secreting T cells appeared (Dhodapkar et al., 2001; Dhodapkar & Steinman, 2002). Aforementioned results suggest that DC can induce antigen-specific T cell tolerance *in vitro* as well as *in vivo*, and have prompted a number of groups to translate these findings into clinical applications. A phase I clinical trial using vitamin D3-treated tolerogenic DC will be started in RA patients at Newcastle University (Harry et al., 2010; Hilkens et al., 2010) (<http://clinicaltrials.gov/ct2/show/study/NCT012352858>). Furthermore, genetic manipulation of DC by overexpressing immune-regulatory molecules or inhibiting or silencing immune-stimulatory molecules promotes tolerogenic function. In line with this, a first safety study using tolerogenic DC treated with antisense oligonucleotides targeting the primary transcripts of the CD40, CD80, and CD86 costimulatory molecules has recently started at the University of Pittsburgh (<http://clinicaltrials.gov/ct2/show/study/NCT00445913>).

3.3. Regulatory T cells

Different T cell subsets have been identified with the ability to suppress immune responses and are currently subdivided based on expression of cell surface markers, production of cytokines and mechanisms of action. Two broad categories of Treg have been described. The first are naturally-occurring thymic-derived regulatory T cells (nTreg) which constitutively express the IL-2 receptor α chain (CD25), and comprise 1-10% of the CD4⁺ T cell population in healthy adults. These cells also express the intracellular transcription factor forkhead box P3 (FOXP3) (Ziegler, 2006), which has demonstrated to be critical for the generation of Treg (Gavin et al., 2007; Bacchetta et al., 2006), and its genetic deficiency results in autoimmune and inflammatory diseases (Wildin & Freitas, 2005). Recently, a unique CpG-rich island within an evolutionary conserved region upstream of exon 1, named TSDR (Treg-specific demethylation region), was demonstrated to be unmethylated in nTreg (Lal & Bromberg, 2009a; Lal et al., 2009b). Demethylation of this region resulted in strong and stable induction of FOXP3. In contrast, conventional CD4⁺ T cells display methylation of the FOXP3 locus. This finding has led to new methods of analysing Treg based on quantitative analysis of methylation patterns of the key transcription factor FOXP3, which may be valuable for quality assessment of *ex vivo* expanded Treg (Wieczorek et al., 2009). There is accumulating

evidence that 2 subsets of nTreg exist: a first population that is derived directly from the thymus; the second derives from CD4⁺CD25⁻ T cell precursors in the periphery. In addition, several other studies have reported the existence of various subsets of (antigen-)induced or adaptive Treg. There are at least two populations of induced Treg (iTreg), subdivided according to different expression of immunosuppressive cytokines: CD4⁺ regulatory T cells type 1 (Tr1) express high levels of interleukin (IL)-10 (Roncarolo et al., 2006; Battaglia et al., 2004), while T helper 3 (Th3) regulatory T cells secrete large amounts of TGF- β (Faria & Weiner, 2006; Carrier et al., 2007). In addition, we have shown the presence of IL-10/TGF- β double-positive Tr1 cells at the single cell level (Cools et al., 2008). Ultimately, only the demonstration of actual suppressive function confirms the presence of Treg.

Numerous immunosuppressive mechanisms described thus far suggest that multiple, redundant mechanisms are required for optimal Treg function *in vivo*. Indeed Treg mediate suppressive effects by several mechanisms including cell contact-mediated suppression, competition for growth factors and secretion of soluble suppressive factors. Several *in vitro* studies have demonstrated that Treg suppress proliferation and IFN- γ production by effector T cells through a direct cell contact-dependent mechanism between suppressor and effector cells, possibly mediated by the expression of cell surface markers, such as glucocorticoid-induced tumor necrosis factor (TNF) receptor-related protein (GITR), cytotoxic T lymphocyte-associated antigen (CTLA-4) and galectin-1 (Shevach, 2009; Garín et al., 2007). Also, cell surface-bound TGF- β has been reported to mediate cell contact-dependent immunosuppression by Treg (Nakamura et al., 2001). Another mechanism for Treg to affect effector T cell activation can be established by modulating DC function. For example, ligation of CD80/CD86 on DC by CTLA-4 on Treg results in expression and activation of IDO (Fallarino et al., 2003), a catabolic enzyme involved in tryptophan degradation. Furthermore, soluble factors such as the immunosuppressive cytokines IL-10, IL-35 (Collison et al., 2007) and TGF- β have been implicated in the suppressive function of Treg. The roles of these cytokines in immunosuppression include cell cycle arrest and inhibition of proliferation, induction of apoptosis, and suppression of DC maturation and function (Li & Flavell, 2008). Moreover, Treg can express cytotoxic molecules, such as granzyme A, granzyme B and perforin, inducing apoptosis of target cells (Grossman et al., 2004; Gondek et al., 2005). Finally, Treg may also attenuate immune responses by competing with effector cells for essential growth factors, such as IL-2 which has been demonstrated to be essential for both Treg and effector cell function (Busse et al., 2010). It is evident from the studies delineated above that the precise mechanisms of suppression by Treg has yet to be fully elucidated.

Various studies have confirmed the importance and therapeutic potential of Treg. A number of commonly used non-specific therapies have been documented to induce immunomodulatory cytokines and to alter Treg function. For instance, rapamycin (sirolimus), an oral inhibitor of the mammalian target of rapamycin (mTor) pathway, promotes the *de novo* generation and enhances the suppressive capacity of Treg (Gao et al., 2007; Monti et al., 2008). This is in contrast to calcineurin inhibitors which inhibit Treg induction. While the action of these drugs is non-specific, strategies to specifically induce Treg are currently the subject of active investigation. These approaches are based on the fact that exposure to antigen increases Treg frequency and/or potency by either expanding

nTreg or inducing the generation of induced Treg from cells that do not originally possess regulatory activity (Long & Wood, 2009). They include adoptive transfer of *ex vivo* generated and/or expanded CD4+CD25+ Treg, and the induction of appropriate Treg populations in patients *in vivo*. Since Treg comprise only a small proportion of peripheral blood CD4+ T cells in human, *ex vivo* expansion of these cells prior to administration to the patient is required. The most commonly used expansion protocol at present is based on stimulation by anti-CD3/anti-CD28 beads in the presence of high doses of recombinant IL-2, supplemented in some protocols with rapamycin (Trzonkowski et al., 2009). This approach is advantageous since the expanded cells can be phenotypically and functionally characterized prior to infusion. Currently, several clinical trials using adoptively transferred Treg are ongoing (Riley et al., 2009). In a phase I/II clinical trial in 28 patients receiving HSCT together with conventional T cells as well as Treg, long-term protection from GVHD and robust immune reconstitution was demonstrated (Di Ianni et al., 2011). In addition, Trzonkowski et al. did not report unexpected adverse effects using *ex vivo* expanded Treg in humans for the treatment of GVHD following HSCT (Trzonkowski et al., 2009). To date, further clinical studies are being planned to test the therapeutic potential of Treg in view of immunosuppression in autoimmunity and in solid organ transplantation.

3.4 Other immune effector cells

3.4.1 B cells

B cells can play a variety of pathogenic roles in human autoimmune diseases. On the one hand, they may serve as potent self-antigen-presenting cells and on the other hand after differentiation into plasma cells they can secrete auto-antibodies that through complexing antigen can promote local inflammatory reactions. Indeed, two major B cell subsets have been demonstrated: (i) early lineage CD20+CD79+CD27+ B cells function primarily as APC expressing MHC and costimulatory antigens that sustain T cell-mediated cellular responses, and (ii) late lineage CD138+ mature plasma cells and CD38+ plasma blasts that relate to the humoral response (Zarkhin et al., 2008; Zarkhin et al., 2010). From these results it is evident that B cells contribute to immunity through production of antibodies, antigen presentation to T cells and secretion of cytokines. The role of B cells as an essential component of the autoimmune reaction that sustains the chronic inflammation has been underlined by successful therapeutic B cell depletion with anti-CD20 monoclonal antibodies. Indeed, rituximab – a chimeric anti-CD20 monoclonal antibody – has been proven to be highly beneficial for patients with certain autoimmune diseases, including RA, MS and type 1 diabetes. However, this treatment also resulted in aggravation of symptoms in a few patients, suggesting that B cells can also protect from autoimmune pathology. In this context, IL-10-producing regulatory CD1d+CD5+ B cells are able to downregulate autoimmune disease initiation, onset, or severity in experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis, contact hypersensitivity, and inflammatory bowel disease, indicating that B cells can also be essential for immunosuppression of autoreactive T cell responses (Iwata et al., 2011; DiLillo et al., 2010). Therefore, B cell-mediated regulation of the immune system may be of great interest for the development of new cell-based therapies for immunosuppression. Indeed, adoptive transfer of *in vitro* activated B cells isolated from successfully treated mice limited disease severity, suggesting a possible role for regulatory B cells (Yanaba et al., 2008).

3.4.2 Natural killer T cells

A T cell subset with regulatory properties that additionally exhibit natural killer cell characteristics has been identified in mice and humans [extensively reviewed elsewhere (Hegde et al., 2010; Pratschke et al., 2009; Wu & Van Kaer, 2009)]. These natural killer T (NKT) cells are a subset of innate lymphocytes that recognize endogenous or exogenous glycolipids in the context of CD1d molecules expressed by APC, such as monocytes, DC and myeloid suppressor cells. Upon antigenic stimulation NKT cells produce a variety of immunomodulatory cytokines, which endow these cells with potent immunoregulatory properties. Therefore, NKT cells have been tested in animal models of various autoimmune diseases, such as type 1 diabetes, experimental autoimmune encephalomyelitis, arthritis and SLE, but so far only with moderate success.

3.4.3 Peripheral blood mononuclear cells (PBMC)

An alternative approach for effective immunosuppression for treatment of autoimmune disease involves the coupling of self-antigen-derived peptides to cellular vehicles using chemical fixatives (Miller et al., 2007). The induction of immunosuppression by this method is indirect and implies that the fixed cells rapidly undergo apoptotic cell death following fixation and subsequently carry over intact peptides to tolerogenic APC for processing and presentation (Smith & Miller, 2006; Turley & Miller, 2007).

To date, the group of Roland Martin from the University of Hamburg (Germany) has started a phase I/IIa study to evaluate the therapeutic use of autologous peripheral blood mononuclear cells (PBMC) in MRI-proven relapsing-remitting MS patients. These PBMC are coupled with a cocktail of 7 myelin peptides associated with MS pathogenesis against which demonstrable responses can be detected in patient subsets (Lutterotti et al., 2008). This first-in-man exploratory study will provide proof-of-concept of the potential for this cell-based immune-therapeutic approach.

4. Conclusion

Cell-based immunotherapy presents an appealing venue as a substantial component of future individualized treatment modalities for a broad scope of medical fields, including cancer immunotherapies, autoimmune diseases and transplantation tolerance.

Increasing knowledge with regard to the biology, function and mode of immunosuppression of immunoregulatory cell populations opens up new possibilities for antigen-specific manipulation of autoimmunity. Ultimately, this will lead to their clinical application. Nonetheless, the complexity and heterogeneity of autoimmunity, in which multiple dysregulated cell types on various genetic backgrounds are involved, may require integration of several tolerance induction mechanisms to restore tolerance. Therefore, the opportunity to intervene before the appearance of epitope spreading (Miller et al., 2007) using tolerogenic strategies in combination with broader immunosuppressive agents, should be further explored. For instance, induction of immunosuppression may be preceded by treatment with biologicals which can function to reduce the self-antigen-specific T cell frequency to a level that can be effectively and permanently suppressed. Strategies that have shown immunosuppressive effects in animal models include the combination of costimulatory blockade reagents and T cell depletion, as well as adoptively transferred Treg (Chen et al., 2005; Bresson & von Herrath, 2008).

Additionally, also the therapeutic benefit of autologous HSCT could be boosted by the addition of regulatory cell populations, such as tolerogenic DC, Treg, or MSC, which have potent immunosuppressive properties.

Numerous questions still remain in view of the translation of bench findings to the bedside. One challenge for immune tolerance induction is the identification of disease subsets to be considered in evaluating treatment response as well as careful and proper choice of patients to be included for clinical trials evaluating the effects of cellular therapies for immunosuppression. Another quest is how to qualitatively and quantitatively measure immunosuppression in patients. In this context, immunological assays may be used as measures of the effect of immune therapies, although their relationship to the disease process remains speculative. As an example, cellular proliferation assays to islet-specific proteins have distinguished responses in diabetic patients from healthy control subjects (Herold et al., 2009). Ideally, therapies for immunosuppression must also be durable. This means that the ability to regulate the autoimmune response has to be permanent or at least for many years following intervention, for instance via the generation of self-antigen-specific Treg. Nevertheless, major concerns to administer a specified cell product as a tolerizing regimen relates to the risk of *in vivo* re-activation, particularly in response to any underlying inflammatory microenvironment. By means of example, it has indeed been shown that a minority of adoptively transferred Treg lose their FOXP3 expression and can even differentiate into effector T cells (Komatsu et al., 2009). Moreover, a number of groups have identified the ability of Treg to differentiate into proinflammatory Th17 cells (Koenen et al., 2008; Voo et al., 2009). Therefore, such side effects need to be blocked and – in the case of DC – several reports demonstrate that exposure to anti-inflammatory cytokines and immunosuppressive agents can condition DC to a tolerogenic state (Steinman & Banchereau, 2007). Recently, we have shown that *in vitro* exposure of *ex vivo* generated DC from MS patients to IL-10 results in IL-10-, but not IL-12-, secreting DC with low expression levels of CD80/86 and an effective capacity to suppress myelin-specific T cell responses *in vitro* (Cools et al., manuscript submitted for publication). Importantly, further *in vitro* treatment of DC with maturation stimuli did not induce phenotypic changes or modifications in the cytokine secretion profile. Other related safety issues include immunogenicity, carcinogenicity, sensitization to donor HLA, lack of clear mechanistic understanding and cost-benefit relations. In particular the absence of transformation potential of *ex vivo* cultured cells needs to be documented before infusion into (immune-compromised) patients, since failure of immune surveillance mechanisms may favour the development of tumors *in vivo*.

In conclusion, improved understanding of the disease pathogenesis of autoimmunity, the genetic defects underlying different forms of autoimmune diseases, and the mechanisms by which regulatory cell populations suppress autoreactive T and B cells will better define the ultimate role of cellular therapies in the treatment of autoimmune disease.

5. Acknowledgement

This work was supported by grant no. G.0168.09 of the Fund for Scientific Research – Flanders, Belgium (FWO-Vlaanderen), by the grants of the University of Antwerp through the Special Research Fund (BOF), Medical Legacy Fund, and the Methusalem funding program, by a grant of the Hercules Foundation - Belgium, by grants of the Charcot

Foundation - Belgium and of the “Belgische Stichting Roeping” - Belgium. NC is a postdoctoral fellow of the Fund for Scientific Research (FWO)-Flanders.

6. References

- Aggarwal S, Pittenger MF. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood*, 105(4):1815-22.
- Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, Mullen Y. (2009). Mesenchymal stem cells suppress B-cell terminal differentiation. *Exp Hematol*, 37(5):604-15.
- Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. *Eur J Immunol*, 35(5):1482-90.
- Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, Azzari C, Ziegler SF, Levings MK, Roncarolo MG. (2006). Defective regulatory and effector T cell functions in patients with FOXP3 mutations. *J Clin Invest*, 116(6):1713-22.
- Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE. (2007). Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. *Blood*, 110(7):2764-7.
- Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. (2006). Expansion of FOXP3^{high} regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. *Blood*, 108(8):2655-61.
- Battaglia M, Gianfrani C, Gregori S, Roncarolo MG. (2004). IL-10-producing T regulatory type 1 cells and oral tolerance. *Ann N Y Acad Sci*, 1029:142-53.
- Batten P, Sarathchandra P, Antoniow JW, Tay SS, Lowdell MW, Taylor PM, Yacoub MH. (2006). Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. *Tissue Eng*, 12(8):2263-73.
- Bettelli E, Korn T, Kuchroo VK. (2007). Th17: the third member of the effector T cell trilogy. *Curr Opin Immunol*, 19(6):652-7.
- Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. *Blood*, 105(5):2214-9.
- Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. (2005). TCR stimulation with modified anti-CD3 mAb expands CD8⁺ T cell population and induces CD8⁺CD25⁺ Tregs. *J Clin Invest*. 115(10):2904-13.
- Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. (2002). Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8⁺ T cell tolerance. *J Exp Med*, 196(12):1627-38.
- Bresson D, von Herrath M. (2008). Resuscitating adaptive Tregs with combination therapies? *Novartis Found Symp*, 292:50-60; discussion 60-7, 122-9, 202-3.
- Burnet M. (1959a). Auto-immune disease. I. Modern immunological concepts. *Br Med J*, 2(5153):645-650.

- Burnet M. (1959b). Auto-immune disease. II. Pathology of the immune response. *Br Med J*, 2(5154):720-725.
- Burt RK, Marmont A, Arnold R, Heipe F, Firestein GS, Carrier E, Hahn B, Barr W, Oyama Y, Snowden J, Kalunian K, Traynor A. (2003). Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus. *Bone Marrow Transplant*, 32 Suppl 1:S49-51.
- Burt RK, Oyama Y, Verda L, Quigley K, Brush M, Yaung K, Statkute L, Traynor A, Barr WG. (2004). Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. *Arthritis Rheum*, 50(8):2466-70.
- Busse D, de la Rosa M, Hobiger K, Thurley K, Flossdorf M, Scheffold A, Höfer T. (2010). Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. *Proc Natl Acad Sci U S A*, 107(7):3058-63.
- Carrier Y, Yuan J, Kuchroo VK, Weiner HL. (2007). Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. *J Immunol*, 178(1):179-85.
- Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M. (1999). Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. *Nat Med*, 5(8):919-23.
- Chen Z, Benoist C, Mathis D. (2005). How defects in central tolerance impinge on a deficiency in regulatory T cells. *Proc Natl Acad Sci U S A*, 102(41):14735-40.
- Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. (2007). The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature*, 450(7169):566-9.
- Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. (2008). Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. *Clin Vaccine Immunol*, 15(2):284-92.
- Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. (2007a). Regulatory T cells and human disease. *Clin Dev Immunol*, 2007:89195.
- Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. (2007b). Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. *J Leukoc Biol*, 82(6):1365-74.
- Cools N, Van Tendeloo VF, Smits EL, Lenjou M, Nijs G, Van Bockstaele DR, Berneman ZN, Ponsaerts P. (2008). Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells. *J Cell Mol Med*, 12(2):690-700.
- Curtsinger JM, Lins DC, Mescher MF. (2003). Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. *J Exp Med*, 197(9):1141-1151.
- Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF. (1999). Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. *J Immunol*, 162(6):3256-3262.
- Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP, Wulffraat N, Buch M, Sampol A, Carreras E, Dubois B, Gruhn B, Güngör T, Pohlreich D, Schuerwegh A, Snarski E, Snowden J, Veys P,

- Fasth A, Lenhoff S, Messina C, Voswinkel J, Badoglio M, Henes J, Launay D, Tyndall A, Gluckman E, Farge D. (2011). Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. *Blood*, Epub ahead of print.
- Dazzi F, van Laar JM, Cope A, Tyndall A. (2007). Cell therapy for autoimmune diseases. *Arthritis Res Ther*, 9(2):206.
- Dhodapkar MV, Steinman RM, Krasovskiy J, Munz C, Bhardwaj N. (2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. *J Exp Med*, 193(2):233-8.
- Dhodapkar MV, Steinman RM. (2002). Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. *Blood*, 100(1):174-7.
- Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF. (2011). Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. *Blood*, 117(14):3921-8.
- Di Nicola M, Carlo-Stella C, Magni M, Milanese M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood*, 99(10):3838-43.
- Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. (1999). Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. *Br J Haematol*, 107(2):275-81.
- DiLillo DJ, Matsushita T, Tedder TF. (2010). B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. *Ann N Y Acad Sci*, 1183:38-57.
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*, 8(4):315-7.
- Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P. (2003). Modulation of tryptophan catabolism by regulatory T cells. *Nat Immunol*, 4(12):1206-12.
- Faria AM, Weiner HL. (2006). Oral tolerance and TGF-beta-producing cells. *Inflamm Allergy Drug Targets*, 5(3):179-90.
- Fehérvári Z, Sakaguchi S. (2004). Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. *Int Immunol*, 16(12):1769-80.
- Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. (1998). Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. *Transplant Proc*, 30(8):4126-7.
- Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation*, 17(4):331-40.

- Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. (2007). Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. *Am J Transplant*, 7(7):1722-32.
- Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. (2007). Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. *Blood*, 109(5):2058-65.
- Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY. (2007). Foxp3-dependent programme of regulatory T-cell differentiation. *Nature*, 445(7129):771-5.
- Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. (2005). Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. *J Immunol*, 174(4):1783-6.
- Greenfield EA, Nguyen KA, Kuchroo VK. (1998). CD28/B7 costimulation: a review. *Crit Rev Immunol*, 18(5):389-418.
- Griffith LM, Pavletic SZ, Tyndall A, Gratwohl A, Furst DE, Forman SJ, Nash RA. (2006). Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. *Biol Blood Marrow Transplant*, 12(6):688-90.
- Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. (2004). Human T regulatory cells can use the perforin pathway to cause autologous target cell death. *Immunity*, 21(4):589-601.
- Haniffa MA, Wang XN, Holtick U, Rae M, Isaacs JD, Dickinson AM, Hilkens CM, Collin MP. (2007). Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. *J Immunol*, 179(3):1595-604.
- Harry RA, Anderson AE, Isaacs JD, Hilkens CM. (2010). Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. *Ann Rheum Dis*, 69(11):2042-50.
- Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. *J Exp Med*, 194(6):769-79.
- Hegde S, Fox L, Wang X, Gumperz JE. (2010). Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. *Immunology*, 130(4):471-83.
- Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM; Type 1 Diabetes TrialNet Research Group. (2009). Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. *Diabetes*, 58(11):2588-95.
- Hilkens CM, Isaacs JD, Thomson AW. (2010). Development of dendritic cell-based immunotherapy for autoimmunity. *Int Rev Immunol*, 29(2):156-83.
- Hough RE, Snowden JA, Wulffraat NM. (2005). Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. *Br J Haematol*, 128(4):432-59.
- Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF. (2011).

- Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. *Blood*, 117(2):530-41.
- Jäger A, Kuchroo VK. (2010). Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. *Scand J Immunol*, 72(3):173-84.
- Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. *Blood*, 105(10):4120-6.
- Jones S, Horwood N, Cope A, Dazzi F. (2007). The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. *J Immunol*, 179(5):2824-31.
- Ju X, Clark G, Hart DN. (2010). Review of human DC subtypes. *Methods Mol Biol*, 595:3-20.
- Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. (2001). Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. *J Exp Med*, 194(6):863-9.
- Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. (2005). Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. *N Engl J Med*, 352(25):2598-608.
- Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. (2008). Human CD25^{high}Foxp3^{pos} regulatory T cells differentiate into IL-17-producing cells. *Blood*, 112(6):2340-52.
- Kohrgruber N, Halanek N, Gröger M, Winter D, Rappersberger K, Schmitt-Egenolf M, Stingl G, Maurer D. (1999). Survival, maturation, and function of CD11c⁻ and CD11c⁺ peripheral blood dendritic cells are differentially regulated by cytokines. *J Immunol*, 163(6):3250-9.
- Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. (2009). Heterogeneity of natural Foxp3⁺ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. *Proc Natl Acad Sci U S A*, 106(6):1903-8.
- Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. (2005). Inducing and expanding regulatory T cell populations by foreign antigen. *Nat Immunol*, 6(12):1219-27.
- Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group. (2007). A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. *N Engl J Med*, 356(6):580-92.
- Kurts C, Heath WR, Kosaka H, Miller JF, Carbone FR. (1998). The peripheral deletion of autoreactive CD8⁺ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). *J Exp Med*, 188(2):415-420.
- Lal G, Bromberg JS. (2009a). Epigenetic mechanisms of regulation of Foxp3 expression. *Blood*, 114(18):3727-35.
- Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, Bromberg JS. (2009b). Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. *J Immunol*, 182(1):259-73.
- Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB,

- Bacigalupo A. (2005). Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. *Biol Blood Marrow Transplant*, 11(5):389-98. PubMed PMID: 15846293.
- Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet*, 371(9624):1579-86.
- Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet*, 363(9419):1439-41.
- Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*, 371(9625):1665-74.
- Li MO, Flavell RA. (2008). Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. *Immunity*, 28(4):468-76.
- Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt Rde W, Omori M, Zhou B, Ziegler SF. (2007). TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. *Annu Rev Immunol*, 25:193-219.
- Liu YJ. (2001). Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. *Cell*, 106(3):259-62.
- Long E, Wood KJ. (2009). Regulatory T cells in transplantation: transferring mouse studies to the clinic. *Transplantation*, 88(9):1050-6.
- Lutterotti A, Sospedra M, Martin R. (2008). Antigen-specific therapies in MS - Current concepts and novel approaches. *J Neurol Sci*, 274(1-2):18-22.
- Lutz MB, Schuler G. (2002). Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? *Trends Immunol*, 23(9):445-9.
- Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F, Locatelli F. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. *Haematologica*, 90(4):516-25.
- Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. (2002). Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. *Science*, 296(5566):346-9.
- Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W; Anti-IL-12 Crohn's Disease Study Group. (2004). Anti-interleukin-12 antibody for active Crohn's disease. *N Engl J Med*, 351(20):2069-79.
- Marigo I, Dazzi F. (2011). The immunomodulatory properties of mesenchymal stem cells. *Semin Immunopathol*, Epub ahead of print.

- Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L. (2008). FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. *Neurology*, 71(16):1261-7.
- Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. *Blood*, 103(12):4619-21.
- Mellor AL, Munn DH. (2004). IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol*, 4(10):762-74.
- Miller SD, Turley DM, Podajil JR. (2007). Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. *Nat Rev Immunol*, 7(9):665-77.
- Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, Bonifacio E, Roncarolo MG, Battaglia M. (2008). Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. *Diabetes*, 57(9):2341-7.
- Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL Jr, Mellor AL. (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. *Science*, 297(5588):1867-70.
- Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, Campbell C, Memon S, Nagle JW, Hakim FT, Gress RE, McFarland HF, Burt RK, Martin R. (2005). Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. *J Exp Med*, 201(5):805-16.
- Nakamura K, Kitani A, Strober W. (2001). Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. *J Exp Med*, 194(5):629-44.
- Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. *J Immunol*, 177(4):2080-7.
- Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med*, 15(1):42-9.
- Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, Wang J, Hu J, Lou X, Chen H. (2008). The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. *Leukemia*, 22(3):593-9.
- O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group. (2009). Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. *Neurology*, 72(1):73-9.
- O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, Steinman RM. (1994). Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. *Immunology*, 82(3):487-93.
- Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. (2001). Allogeneic stem cell transplantation for Evans syndrome. *Bone Marrow Transplant*, 28(9):903-5.
- Penna G, Sozzani S, Adorini L. (2001). Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. *J Immunol*, 167(4):1862-6.

- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science*, 284(5411):143-7.
- Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. (2007). A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. *Gastroenterology*, 133(5):1414-22.
- Popat U, Krance R. (2004). Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. *Br J Haematol*, 126(5):637-49.
- Pratschke J, Stauch D, Kotsch K. (2009). Role of NK and NKT cells in solid organ transplantation. *Transpl Int*, 22(9):859-68.
- Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. *Haematologica*, 92(7):881-8.
- Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. (2007). Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. *J Leukoc Biol*, 82(4):887-93.
- Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. (2011). Plasmacytoid dendritic cells: recent progress and open questions. *Annu Rev Immunol*, 29:163-83.
- Riley JL, June CH, Blazar BR. (2009). Human T regulatory cell therapy: take a billion or so and call me in the morning. *Immunity*, 30(5):656-65.
- Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. (2006). Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunol Rev*, 212:28-50.
- Sabatos-Peyton CA, Verhagen J, Wraith DC. (2010). Antigen-specific immunotherapy of autoimmune and allergic diseases. *Curr Opin Immunol*, 22(5):609-15.
- Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. (2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. *Immunity*, 12(4):431-440.
- Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. *Blood*, 109(1):228-34.
- Schwartz RH. (2003). T cell anergy. *Annu Rev Immunol*, 21:305-34.
- Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH; Ustekinumab MS Investigators. (2008). Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. *Lancet Neurol*, 7(9):796-804.
- Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ. (2002). Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. *Stem Cells* 20(6):530-41.
- Shevach EM. (2009). Mechanisms of foxp3+ T regulatory cell-mediated suppression. *Immunity*, 30(5):636-45.
- Smith CE, Miller SD. (2006). Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. *J Autoimmun*, 27(4):218-31.

- Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. *Stem Cells*, 24(1):74-85.
- Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. *Blood*, 113(26):6576-83.
- Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood*, 107(4):1484-90.
- Steinman RM, Banchereau J. (2007). Taking dendritic cells into medicine. *Nature*, 449(7161):419-26.
- Steinman RM, Hawiger D, Nussenzweig MC. (2003). Tolerogenic dendritic cells. *Annu Rev Immunol*, 21:685-711.
- Steinman RM, Nussenzweig MC. (2002). Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. *Proc Natl Acad Sci U S A*, 99(1):351-358.
- Strom TB, Koulmanda M. (2009). Recently discovered T cell subsets cannot keep their commitments. *J Am Soc Nephrol*, 20(8):1677-80.
- Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK. (2006). Immune surveillance in multiple sclerosis patients treated with natalizumab. *Ann Neurol*, 59(5):743-7.
- Süss G, Shortman K. (1996). A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. *J Exp Med*, 183(4):1789-96.
- Swiecki M, Colonna M. (2010). Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. *Immunol Rev*, 234(1):142-62.
- Tabera S, Pérez-Simón JA, Díez-Campelo M, Sánchez-Abarca LI, Blanco B, López A, Benito A, Ocio E, Sánchez-Guijo FM, Cañizo C, San Miguel JF. (2008). The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. *Haematologica*, 93(9):1301-9.
- Teng YK, Verburg RJ, Sont JK, van den Hout WB, Breedveld FC, van Laar JM. (2005). Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. *Arthritis Rheum*, 52(8):2272-6.
- Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK. (2000). Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. *Lancet*, 356(9231):701-7.
- Trombetta ES, Mellman I. (2005). Cell biology of antigen processing in vitro and in vivo. *Annu Rev Immunol*, 23:975-1028.
- Trzonkowski P, Bieniaszewska M, Juścińska J, Dobyszek A, Krzystyniak A, Marek N, Myśliwska J, Hellmann A. (2009). First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. *Clin Immunol*, 133(1):22-6.

- Turley DM, Miller SD. (2007). Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. *J Immunol*, 178(4):2212-20.
- Tyndall A, Saccardi R. (2005). Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. *Clin Exp Immunol*, 141(1):1-9.
- Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, Goossens H, de Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama H, Berneman ZN. (2010). Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. *Proc Natl Acad Sci U S A*, 107(31):13824-9.
- Victor FC, Gottlieb AB, Menter A. (2003). Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. *Clin Dermatol*, 21(5):392-7.
- Vincenti F, Luggen M. (2007). T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. *Annu Rev Med*, 58:347-58.
- Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, Bover L, Hanabuchi S, Khalili J, Marinova E, Zheng B, Littman DR, Liu YJ. (2009). Identification of IL-17-producing FOXP3⁺ regulatory T cells in humans. *Proc Natl Acad Sci U S A*, 106(12):4793-8.
- Weaver CT, Hatton RD. (2009). Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. *Nat Rev Immunol*, 9(12):883-9.
- Wieczorek G, Asemussen A, Model F, Turbachova I, Floess S, Liebenberg V, Baron U, Stauch D, Kotsch K, Pratschke J, Hamann A, Loddenkemper C, Stein H, Volk HD, Hoffmüller U, Grützkau A, Mustea A, Huehn J, Scheibenbogen C, Olek S. (2009). Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. *Cancer Res*, 69(2):599-608.
- Wildin RS, Freitas A. (2005). IPEX and FOXP3: clinical and research perspectives. *J Autoimmun*, 25 Suppl:56-62.
- Wu L, Van Kaer L. (2009). Natural killer T cells and autoimmune disease. *Curr Mol Med*, 9(1):4-14.
- Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. (2008). A regulatory B cell subset with a unique CD1dhiCD5⁺ phenotype controls T cell-dependent inflammatory responses. *Immunity*, 28(5):639-50.
- Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. *Nature*, 356(6364):63-6.
- Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood*, 106(5):1755-61.
- Zarkhin V, Chalasani G, Sarwal MM. (2010). The yin and yang of B cells in graft rejection and tolerance. *Transplant Rev (Orlando)*, 24(2):67-78.

- Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, Salvatierra O, Sarwal MM. (2008). Characterization of intra-graft B cells during renal allograft rejection. *Kidney Int*, 74(5):664-73.
- Zhou H, Jin Z, Liu J, Yu S, Cui Q, Yi D. (2008). Mesenchymal stem cells might be used to induce tolerance in heart transplantation. *Med Hypotheses*, 70(4):785-7.
- Zhou L, Chong MM, Littman DR. (2009). Plasticity of CD4⁺ T cell lineage differentiation. *Immunity*, 30(5):646-55.
- Ziegler SF. (2006). FOXP3: of mice and men. *Annu Rev Immunol*, 24:209-26.

Immunosuppression - Role in Health and Diseases

Edited by Dr. Suman Kapur

ISBN 978-953-51-0152-9

Hard cover, 470 pages

Publisher InTech

Published online 24, February, 2012

Published in print edition February, 2012

A need for a book on immunology which primarily focuses on the needs of medical and clinical research students was recognized. This book, "Immunosuppression - Role in Health and Diseases" is relatively short and contains topics relevant to the understanding of human immune system and its role in health and diseases. Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Therapeutic immunosuppression has applications in clinical medicine, ranging from prevention and treatment of organ/bone marrow transplant rejection, management of autoimmune and inflammatory disorders. It brings important developments both in the field of molecular mechanisms involved and active therapeutic approaches employed for immunosuppression in various human disease conditions. There was a need to bring this information together in a single volume, as much of the recent developments are dispersed throughout biomedical literature, largely in specialized journals. This book will serve well the practicing physicians, surgeons and biomedical scientists as it provides an insight into various approaches to immunosuppression and reviews current developments in each area.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Nathalie Cools, Viggo F. I. Van Tendeloo and Zwi N. Berneman (2012). Cellular Therapies for Immunosuppression, *Immunosuppression - Role in Health and Diseases*, Dr. Suman Kapur (Ed.), ISBN: 978-953-51-0152-9, InTech, Available from: <http://www.intechopen.com/books/immunosuppression-role-in-health-and-diseases/cellular-therapies-for-immunosuppression>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen